Lilly's Omvoh® (mirikizumab) recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's disease
Portfolio Pulse from
Eli Lilly's Omvoh® (mirikizumab) has received a positive opinion from the CHMP for approval in the EU for treating adults with moderately to severely active Crohn's disease. The decision is based on the Phase 3 VIVID-1 trial, which showed significant benefits. Lilly has also submitted Omvoh for approval in the U.S., with a decision expected in the first half of 2025.
December 13, 2024 | 1:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's Omvoh® has been recommended for approval by the CHMP in the EU for Crohn's disease, with a U.S. decision expected in 2025. This could enhance Lilly's product portfolio and market position.
The positive CHMP opinion for Omvoh® in the EU is a significant regulatory milestone for Eli Lilly, potentially leading to increased market share in the Crohn's disease treatment space. The upcoming U.S. decision further adds to the potential positive impact on Lilly's stock.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90